Hologic, Inc. (NASDAQ:HOLX) Stake Lifted by Otter Creek Advisors LLC

Otter Creek Advisors LLC grew its holdings in shares of Hologic, Inc. (NASDAQ:HOLXGet Rating) by 57.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 64,074 shares of the medical equipment provider’s stock after acquiring an additional 23,281 shares during the period. Hologic comprises about 2.0% of Otter Creek Advisors LLC’s investment portfolio, making the stock its 9th biggest holding. Otter Creek Advisors LLC’s holdings in Hologic were worth $4,922,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the company. Norges Bank bought a new stake in Hologic in the fourth quarter valued at about $189,247,000. TD Asset Management Inc. grew its position in shares of Hologic by 78.9% in the 4th quarter. TD Asset Management Inc. now owns 2,656,184 shares of the medical equipment provider’s stock valued at $203,357,000 after acquiring an additional 1,171,229 shares during the period. Sound Shore Management Inc. CT bought a new position in shares of Hologic in the 1st quarter valued at about $79,621,000. Renaissance Technologies LLC raised its stake in Hologic by 994.7% in the 4th quarter. Renaissance Technologies LLC now owns 674,361 shares of the medical equipment provider’s stock worth $51,629,000 after purchasing an additional 612,761 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. raised its position in shares of Hologic by 112.8% in the 4th quarter. Candriam Luxembourg S.C.A. now owns 1,139,174 shares of the medical equipment provider’s stock valued at $87,215,000 after buying an additional 603,846 shares in the last quarter. 92.70% of the stock is currently owned by institutional investors and hedge funds.

Hologic Stock Performance

Shares of NASDAQ:HOLX traded up $0.20 during mid-day trading on Friday, reaching $71.40. 1,144,927 shares of the company traded hands, compared to its average volume of 1,577,400. The company’s 50 day moving average price is $71.14 and its 200-day moving average price is $72.79. The firm has a market cap of $17.83 billion, a PE ratio of 12.04, a PEG ratio of 0.81 and a beta of 1.05. The company has a debt-to-equity ratio of 0.57, a current ratio of 3.91 and a quick ratio of 3.32. Hologic, Inc. has a 52 week low of $66.58 and a 52 week high of $81.04.

Hologic (NASDAQ:HOLXGet Rating) last posted its quarterly earnings results on Wednesday, July 27th. The medical equipment provider reported $0.95 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.69 by $0.26. Hologic had a return on equity of 37.48% and a net margin of 28.93%. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $896.71 million. During the same quarter in the prior year, the company earned $1.33 EPS. The business’s revenue was down 14.2% compared to the same quarter last year. On average, equities analysts expect that Hologic, Inc. will post 5.82 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Jan Verstreken sold 6,500 shares of the business’s stock in a transaction dated Tuesday, May 17th. The stock was sold at an average price of $78.80, for a total value of $512,200.00. Following the completion of the sale, the insider now directly owns 64,191 shares of the company’s stock, valued at approximately $5,058,250.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.54% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on HOLX shares. UBS Group started coverage on shares of Hologic in a research report on Wednesday, July 20th. They issued a “neutral” rating and a $73.00 price target on the stock. SVB Leerink increased their price target on shares of Hologic to $85.00 and gave the company an “outperform” rating in a research report on Tuesday, May 17th. BTIG Research lowered shares of Hologic from a “buy” rating to a “neutral” rating in a research report on Monday, July 18th. Morgan Stanley lowered their price target on shares of Hologic from $72.00 to $70.00 and set an “equal weight” rating on the stock in a report on Thursday, July 28th. Finally, Bank of America downgraded shares of Hologic from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $81.00 to $75.00 in a report on Wednesday, July 20th. Seven research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Hologic presently has a consensus rating of “Hold” and an average price target of $76.71.

About Hologic

(Get Rating)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.

Recommended Stories

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLXGet Rating).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.